Delivery Order SPE2DR25D2100-SPE2DR26FA1CX
- Not listed
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on November 17, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 150 mL quantities, with a contract ceiling value of $2,802.86. This is a firm fixed-price delivery order with an ultimate completion date of November 18, 2025, with no set-aside designation applied. AmerisourceBergen, headquartered in Conshohocken, Pennsylvania—the location of performance for this contract—is a major pharmaceutical...
- The Defense Logistics Agency awarded a $1,526.88 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on January 9, 2026, with an ultimate completion date of January 12, 2026. This non-set-aside, firm fixed-price delivery order was performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp is a subsidiary of Cencora, Inc., a major pharmaceutical distributor serving federal government healthcare systems, particularly...
- The Defense Logistics Agency awarded a delivery order valued at $2,475.27 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension in a 180 ml quantity. The contract is a firm fixed-price delivery order with no set-aside designation, awarded on January 7, 2026, with an ultimate completion date of January 8, 2026. Performance will be executed from the contractor's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen Drug...
- The Defense Logistics Agency awarded a delivery order valued at $2,276.24 to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on September 15, 2025, with an ultimate completion date of September 16, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999.00 vehicle running through...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $1,721.55 for Quillivant XR 25 mg/5 ml suspension (150 ml) with a firm fixed price structure. The award was made on December 5, 2025, with an ultimate completion date of December 8, 2025. This non-set-aside contract will be performed at the company's corporate office location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its headquarters as a major pharmaceutical distributor serving...
- The Defense Logistics Agency awarded a delivery order valued at $1,577.04 to AmerisourceBergen Drug Corp for the supply of Quillivant XR 25 mg/5 ml suspension (120 ml) on July 29, 2025, with completion scheduled for July 30, 2025. This is a firm fixed-price delivery order with no set-aside designation, competitively awarded under open competition. The pharmaceutical product will be delivered to the company's facility in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on July 21, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 60 ml quantities, valued at $1,182.78. This firm fixed-price delivery order, with an ultimate completion date of July 22, 2025, represents a non-competitive set-aside award and will be performed at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract is issued as a child order under AmerisourceBergen's...
- The Defense Logistics Agency awarded a $1,218.48 firm fixed-price delivery order to AmerisourceBergen Drug Corp on November 3, 2025, for the supply of Quillivant XR 25 mg/5 ml suspension in 180 ml quantities, with performance completion scheduled for November 4, 2025. This non-set-aside award was competitively procured and will be performed at the contractor's facility in Conshohocken, Pennsylvania. The delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The U.S. Defense Logistics Agency Medical Supply Chain awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Quillivant XR 25 mg/5 mL suspension in 60 mL quantities, with a ceiling value of $3,991.48. This non-set-aside, competitively awarded contract utilizes firm fixed pricing and is scheduled for ultimate completion by September 23, 2025. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, will...
- The Defense Logistics Agency awarded a $6,392.32 delivery order to AmerisourceBergen Drug Corp for Quillivant XR 25 mg/5 ml suspension (120 ml) on December 10, 2025, with completion scheduled for December 11, 2025. This is a firm fixed-price delivery order with no set-aside designation, issued under open competition. The product will be performed from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's...
- SPE2DR25D2100Indefinite Delivery Contract
- SPE2DR25D2100-SPE2DR26FA1CXDelivery Order
The Defense Logistics Agency awarded a $2,751.84 delivery order to AmerisourceBergen Drug Corp on January 12, 2026, for Quillivant XR 25 mg/5 ml suspension in 150 ml quantities, with delivery expected by January 13, 2026. This non-set-aside, firm fixed-price order was competitively awarded and will be performed at the contractor's Conshohocken, Pennsylvania facility. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc. (doing business as AmerisourceBergen), is a major pharmaceutical distributor providing critical medical supplies to federal healthcare systems. This delivery order is issued under AmerisourceBergen's comprehensive Indefinite Delivery Contract with DLA Troop Support Medical valued at $999,999,999.00 through December 2026. The underlying IDC serves as a global pharmaceutical support vehicle enabling the contractor to supply a broad range of medications, vaccines, medical devices, and specialized healthcare commodities to support military healthcare programs worldwide, including the Defense Health Agency and U.S. Coast Guard. Quillivant XR, an attention-deficit/hyperactivity disorder medication, represents one of the specialized pharmaceuticals delivered through this extensive contract vehicle supporting Department of Defense healthcare operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Loading... | ||||